让老百姓用得起好药,上海全力推进仿制药质量疗效一致性评价

2018-07-25 陈斯斯 澎湃新闻

2015年起,国家通过推进药品审评审批制度改革来加快新药、好药的上市,在这方面,上海已经取得哪些进展?7月24日,上海市食药监局副局长陈尧水在上海市政府新闻发布会上表示,中国经过改革开放四十年,基本解决了缺医少药问题,现在的突出问题是要让老百姓用得上新药、好药。为此,上海市食药监局主要开展了三方面工作。一是在全国率先开展药品上市许可人制度试点,来促进创新研发生产,加快新药上市。经过两年多努力,上海

2015年起,国家通过推进药品审评审批制度改革来加快新药、好药的上市,在这方面,上海已经取得哪些进展?

7月24日,上海市食药监局副局长陈尧水在上海市政府新闻发布会上表示,中国经过改革开放四十年,基本解决了缺医少药问题,现在的突出问题是要让老百姓用得上新药、好药。为此,上海市食药监局主要开展了三方面工作。

一是在全国率先开展药品上市许可人制度试点,来促进创新研发生产,加快新药上市。经过两年多努力,上海已形成了一整套可复制、可推广的制度和若干实践案例,极大地激发了创新活力,集聚了一大批创新研发企业和生产企业结对试点,催生了一系列本土研发的创新药、明星药。上海已有32个具有自主知识产权、尚未在国内外上市的1类新药申请临床试验和上市许可,其中上海和记黄埔自主研发的治疗晚期结直肠癌的“呋喹替尼”预计将在年内上市。由中科院上海药物所和上海绿谷制药联合研发的突破性的抗老年痴呆症药物GV-971将于年内递交上市申请。

二是全力推进仿制药质量和疗效一致性评价,提高市场竞争力,让老百姓用得上、用得起与原研药相等的好药。经过多方协同推进,本市仿制药一致性评价工作正顺利开展,其中迪赛诺制药抗艾滋病的依非韦伦片、上海安必生制药治疗儿童哮喘的孟鲁司特钠咀嚼片和普通片均为全国首家通过一致性评价。特别值得一提的是:安必生是国内首家持有药品上市许可的药品研发机构,其在国内上市的孟鲁司特钠片与在美国上市的产品为共线生产,质量与疗效完全一致。

三是加快进口药品上市,满足市场急需。在贯彻落实国家进口药相关政策的同时,市食药监局积极作为,一方面充分发挥上海市食品药品检验所药品口岸检验的作用,加快检验和通关,同时积极与国家药监局沟通,将临床紧缺的治疗乳腺癌药物赫赛汀的口岸检验与上市销售同步进行,以缩短药品供应时间。另一方面积极争取国外已上市、在我国尚无同品种产品获准注册的抗肿瘤新药在上海先行定点使用,满足临床急需。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906880, encodeId=72a219068808b, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Feb 24 17:46:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261427, encodeId=8eb4126142ee7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444406, encodeId=9fb414444066d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031854, encodeId=c99610318546c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 25 17:46:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2019-02-24 zhanfl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906880, encodeId=72a219068808b, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Feb 24 17:46:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261427, encodeId=8eb4126142ee7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444406, encodeId=9fb414444066d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031854, encodeId=c99610318546c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 25 17:46:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-27 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906880, encodeId=72a219068808b, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Feb 24 17:46:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261427, encodeId=8eb4126142ee7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444406, encodeId=9fb414444066d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031854, encodeId=c99610318546c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 25 17:46:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-27 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906880, encodeId=72a219068808b, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Sun Feb 24 17:46:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261427, encodeId=8eb4126142ee7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444406, encodeId=9fb414444066d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jul 27 05:46:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031854, encodeId=c99610318546c, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 25 17:46:00 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-25 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

振奋!国家两大部长为百姓发民生大红包了!

党的十九大报告中明确宣示:增进民生福祉是发展的根本目的。必须多谋民生之利、多解民生之忧,我国在幼有所育、学有所教、劳有所得、病有所医、老有所养、住有所居、弱有所扶上不断取得新进展。人民生活赶上好时代,不再为吃饱穿暖发愁,最怕的就是进医院,医疗和医保成为民生的重头戏。10月22日,国家卫生计生委主任李斌、国家人力资源社会保障部党组书记、部长尹蔚民出席十九大记者招待会,回应民生关切,为百姓送上丰富大礼

不缺医疗资源为啥百姓感觉“看病难”?政协委员:资源不均 基层空虚

看病贵,看病难,一病返贫局面何时完?医疗健康关乎民生,如何能在医院不大排长队,如何能在农村享受名医资源,如何能不因看病拖垮整个家庭成了百姓心尖尖挂着的事。在全国政协委员、中国医学科学院阜外心血管病医院医保办公室主任敖虎山看来,中国不缺乏医疗资源,老百姓看病难、看病贵还是因为医疗资源分布不平衡导致。“医疗资源不平衡是自古以来一直存在的。在中国,主要医疗资源都集中在北京和上海,而老百姓得病了,又都想

中医药法实施一周年:中医药服务离百姓更近

引人关注的《中华人民共和国中医药法》自去年7月1日实施至今已满一年。一年来,法治体系“踩足油门”加速构建,不断“激活”中医药服务供给能力,给老百姓带来诸多实惠,为护佑人类健康做出新的贡献。

成都市副市长:“成都路径”提升百姓中医药获得感

近年来,四川省把中医药发展摆在社会民生的重要战略位置,省政府去年5月7日召开了四川省中医药发展大会,11月10日又召开了中医药健康产业发展推进大会,王国强局长亲临到会,并作出重要指示。我们按照国家中医药管理局和省中医药管理局的要求,以打造中医药健康服务标杆城市为目标,积极探索提升老百姓中医药服务获得感的“成都路径”,为人民群众提供全方位全周期健康服务。